# Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

> **NCT01500551** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 302 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT01500551
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-18
- **Primary completion:** 2025-02-12
- **Final completion:** 2025-02-12
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500551, "Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01500551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*